Natco Pharma Ltd receives seven Form 483 observations after US FDA inspection of its Kothur facility
- Inspection ran from November 12 to 20, 2026, at the formulation manufacturing facility in Kothur, Hyderabad.
- The company described the observations as procedural and said it was confident of addressing them within the stipulated timelines.
